50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
https://www.vrtx.com
Setor(es): Healthcare
Indústria: Biotechnology
Funcionários Integrais: 4.800
Nome | Título | Pagar | Exercido | Nascido em |
---|---|---|---|---|
Dr. Jeffrey Marc Leiden M.D., Ph.D. | Executive Chairman | 92,93k | 11,49M | 1956 |
Dr. Reshma Kewalramani FASN, M.D. | CEO, President & Director | 5,22M | N/A | 1973 |
Mr. Charles F. Wagner Jr. | Executive VP & CFO | 2,06M | N/A | 1968 |
Mr. Stuart A. Arbuckle B.Sc. | Executive VP & COO | 2,7M | 1,26M | 1966 |
Dr. David M. Altshuler M.D., Ph.D. | Executive VP of Global Research & Chief Scientific Officer | 2,03M | 3,09M | 1965 |
Ms. Kristen C. Ambrose | Senior VP & Chief Accounting Officer | N/A | N/A | 1977 |
Mr. Mike Tirozzi | SVP and Chief Information & Data Officer | N/A | N/A | N/A |
Susie Lisa | Senior Vice President of Investor Relations | N/A | N/A | N/A |
Mr. Damian W. Wilmot Esq. | Senior VP, Chief Risk and Compliance Officer | N/A | N/A | 1976 |
Mr. Jonathan Biller J.D. | Executive VP & Chief Legal Officer | N/A | N/A | 1964 |
O QualityScore de governança da ISS da Vertex Pharmaceuticals Incorporated a partir de 28 de novembro de 2023 é 8. As principais pontuações para Auditoria são: 9; Conselho: 6; Direitos de Acionistas: 6; Compensação: 8.